Treating Pediatric Depression Effectively

Treating Pediatric Depression Effectively

Diagnosis: Major Depression

Recommend one FDA-approved drug, one off-label drug, and one nonpharmacological intervention for treating Major Depression Disorder in children and adolescents.
Explain the risk assessment you would use to inform your treatment decision making.
What are the risks and benefits of the FDA-approved medicine?
What are the risks and benefits of the off-label drug?
Explain whether clinical practice guidelines exist for Major Depression Disorder and, if so, use them to justify your recommendations. If not, explain what information you would need to take into consideration.
Support your reasoning with at least three scholarly resources, one each on the FDA-approved drug, the off-label, and a non-medication intervention for the disorder. Attach the PDFs of your sources.

2 Pages,

References x 3

Check our essay writing services here

Hilt, R. J., & Nussbaum, A. M. (2016). DSM-5 pocket guide for child and adolescent mental healthLinks to an external site.. American Psychiatric Association Publishing.
- Chapter 14, “Psychosocial Interventions”
- Chapter 15, “Psychotherapeutic Interventions”
- Chapter 16, “Psychopharmacological Interventions”Links to an external site.
Thapar, A., Pine, D. S., Leckman, J. F., Scott, S., Snowling, M. J., & Taylor, E. A. (2015). Rutter’s child and adolescent psychiatry (6th ed.). Wiley Blackwell.
- Chapter 43, “Pharmacological, Medically-Led and Related Treatments”

Benefits: Fluoxetine is the only FDA-approved selective serotonin reuptake inhibitor (SSRI) for treating depression in children and adolescents aged 8 and older. It has been shown to improve mood, alleviate depressive symptoms, and increase functionality in young patients.
Risks: Potential side effects include nausea, headache, insomnia, fatigue, and an increased risk of suicidal thoughts, especially in the early stages of treatment. Monitoring is essential during initial treatment and dosage adjustments.